LT3001 Drug Product clinical trials

BRIGHT - A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS)

This study, called BRIGHT, is testing a new medicine called LT3001 for people who have recently had a stroke. It's in an early stage (Phase 2), focusing on whether the medicine is safe and if it helps people recover. Some people will get the real medicine, others a dummy treatment.